Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03023202

UWCCC Molecular Tumor Board Registry

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematologic Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Neoplasms Neoplasms by Site Solid Neoplasm

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

Location status: Recruiting

Location contact

Cancer Connect

CONTACT

[email protected]

800-622-8922

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically suspected or histologically confirmed solid or hematological malignancy
  • Undergoing genetic testing of tumor
  • Ability to understand written informed consent document
  • Willingness to sign written informed consent document

Exclusion criteria

  • Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Treatment and study plan

PMMTB (Precision Medicine Molecular Tumor Board)

Other

PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

Primary outcomes

  1. Frequency of acceptance of molecular tumor board recommendations

    Time frame: Up to 5 years

    How often the molecular tumor board's recommendations are accepted

  2. Benefit from PMMTB recommended treatment

    Time frame: Up to 5 years

    Whether patients benefit from PMMTB recommended treatment

Secondary outcomes

  1. Correlation of mutations with protein overexpression

    Time frame: Up to 5 years

    Correlate mutations identified in tumor tissue with protein overexpression

  2. Correlations of mutations with circulating tumor DNA

    Time frame: Up to 5 years

    Correlate mutations identified in tumor tissue with circulating tumor DNA

  3. Correlations of mutations with spheroid culture investigations

    Time frame: Up to 5 years

    Correlate mutations identified in tumor tissue with spheroid culture investigations

Study contacts

Contact information is provided by the study sponsor or research team.

Cancer Connect

CONTACT

[email protected]

8006228922

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

UWCCC Precision Medicine Molecular Tumor Board Registry

Important dates

Study start
2016
Primary completion
2029
Study completion
2029
First posted
Jan 18, 2017
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.